Twelve research firms issued Nashville, Tenn.-based AmSurg shares a "buy" rating, according to the Daily Quint.
Here are four notes:
1. Among the analysts covering the stock, the 12-month price target is $87.88.
2. On Nov. 4, 2016, Zacks issued AmSurg shares a "hold" rating.
3. AmSurg reported earnings per share of $1.13 last quarter.
4. In the third quarter, AmSurg surpassed analysts' estimates of $770.2 million and generated revenue of $822.2 million.